Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02332980
What this trial is testing

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+20 more
Mayo Clinic 65
Testing effectiveness (Phase 2)Study completedNCT03390296
What this trial is testing

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center 50
Early research (Phase 1)WithdrawnNCT07428486
What this trial is testing

FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Phase IFLAG ChemotherapyLisaftoclax+3 more
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT02846623
What this trial is testing

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic Leukemia+2 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT02044796
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Who this might be right for
Acute Biphenotypic Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome+3 more
Fred Hutchinson Cancer Center 199
Testing effectiveness (Phase 2)Study completedNCT00037596
What this trial is testing

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Study completedNCT00315705
What this trial is testing

Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaRelapsed Leukemia
Genzyme, a Sanofi Company 50
Early research (Phase 1)Temporarily pausedNCT07388563
What this trial is testing

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Who this might be right for
Lymphoma, T Cell, PeripheralT-cell LymphomaAngioimmunoblastic T-cell Lymphoma+3 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Early research (Phase 1)Ended earlyNCT05038644
What this trial is testing

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Who this might be right for
Acute Myeloid LeukemiaT Cell Acute Lymphoblastic LeukemiaT Cell Lymphoblastic Lymphoma
Ehab L Atallah 22
Not applicableStudy completedNCT00996047
What this trial is testing

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
SWOG Cancer Research Network 3,341
Testing effectiveness (Phase 2)Looking for participantsNCT05745714
What this trial is testing

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Very early researchNot Yet RecruitingNCT06986434
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Who this might be right for
Relapsed or Refractory Plasma Cell NeoplasmsLymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences 20
Very early researchNot Yet RecruitingNCT06786299
What this trial is testing

Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia(AML)
First Affiliated Hospital of Zhejiang University 18
Testing effectiveness (Phase 2)Ended earlyNCT01685021
What this trial is testing

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
MorphoSys AG 22
Early research (Phase 1)Study completedNCT02594384
What this trial is testing

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
OrphAI Therapeutics 62
Early research (Phase 1)Not Yet RecruitingNCT07841002
What this trial is testing

CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)
Liping Dou 12
Next Page
26